tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

APRE Stock Latest News

Aprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating
RatingsAprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating
19d ago
APRE
Aprea Therapeutics Reports Ongoing Financial Challenges
PremiumCompany Announcements
Aprea Therapeutics Reports Ongoing Financial Challenges
20d ago
APRE
Aprea Therapeutics Reports Q3 Results and Clinical Updates
PremiumCompany Announcements
Aprea Therapeutics Reports Q3 Results and Clinical Updates
21d ago
8K
APRE
Aprea Therapeutics reports Q3 EPS (47c) vs. (64) last year
PremiumThe Fly
Aprea Therapeutics reports Q3 EPS (47c) vs. (64) last year
21d ago
APRE
Aprea Therapeutics sees cash runway into 4Q26
PremiumThe Fly
Aprea Therapeutics sees cash runway into 4Q26
21d ago
APRE
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors
PremiumCompany AnnouncementsAprea Therapeutics Advances ATRN-119 Study for Solid Tumors
1M ago
APRE
Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors
Premium
Company Announcements
Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors
1M ago
APRE
Aprea Therapeutics Reports Promising Trial Results for APR-1051
Premium
Company Announcements
Aprea Therapeutics Reports Promising Trial Results for APR-1051
1M ago
8K
APRE
Aprea Therapeutics provides update from ACESOT-1051 t rial
PremiumThe Fly
Aprea Therapeutics provides update from ACESOT-1051 t rial
1M ago
APRE
Aprea Therapeutics: Strategic Advancements and Unique Positioning Drive Buy Recommendation
PremiumRatings
Aprea Therapeutics: Strategic Advancements and Unique Positioning Drive Buy Recommendation
2M ago
APRE
Aprea Therapeutics Shifts Focus to Combination Therapies
PremiumCompany Announcements
Aprea Therapeutics Shifts Focus to Combination Therapies
2M ago
8K
APRE
Aprea Therapeutics establishes RP2D for ATRN-119
PremiumThe Fly
Aprea Therapeutics establishes RP2D for ATRN-119
2M ago
APRE
Aprea Therapeutics Highlights Progress in Clinical Trials
PremiumCompany AnnouncementsAprea Therapeutics Highlights Progress in Clinical Trials
3M ago
8K
APRE
Positive Outlook for Aprea Therapeutics: Promising Progress in WEE1i and ATRi Candidates Amidst Challenges
Premium
Ratings
Positive Outlook for Aprea Therapeutics: Promising Progress in WEE1i and ATRi Candidates Amidst Challenges
4M ago
APRE
Aprea Therapeutics Reports Promising Q2 2025 Results
Premium
Company Announcements
Aprea Therapeutics Reports Promising Q2 2025 Results
4M ago
APRE
Aprea Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Aprea Therapeutics Reports Q2 2025 Financial Results
4M ago
8K
APRE
Aprea Therapeutics reports Q2 EPS (53c) vs. (58c) last year
PremiumThe Fly
Aprea Therapeutics reports Q2 EPS (53c) vs. (58c) last year
4M ago
APRE
Aprea Therapeutics sees cash runway into 2Q26
PremiumThe Fly
Aprea Therapeutics sees cash runway into 2Q26
4M ago
APRE
Aprea Therapeutics announces new preclinical data, update on APR-1051
PremiumThe Fly
Aprea Therapeutics announces new preclinical data, update on APR-1051
5M ago
APRE
Aprea Therapeutics Confirms Directors and Accounting Firm
PremiumCompany AnnouncementsAprea Therapeutics Confirms Directors and Accounting Firm
6M ago
8K
APRE
Buy Rating for Aprea Therapeutics: Strong Clinical Progress and Financial Stability
Premium
Ratings
Buy Rating for Aprea Therapeutics: Strong Clinical Progress and Financial Stability
7M ago
APRE
Aprea Therapeutics Reports Q1 2025 Progress and Financials
Premium
Company Announcements
Aprea Therapeutics Reports Q1 2025 Progress and Financials
7M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >